Travel Insurance with Crohn's Disease: What Gets Your Claim Paid

Your claim can be denied even with a declared condition. The difference comes down to three specific policy mechanics most IBD travellers never read.

IBD travel insurance: why declaration is necessary but not sufficient

Declaring your Crohn's disease or ulcerative colitis is the minimum, not the finish line. Insurers can still reject a claim after a declared condition if the specifics of your medication, your timing, or your medical records fall outside the policy's definitions. Most people with IBD focus entirely on whether to declare, and miss the three mechanisms that actually determine whether a claim is paid.

This article covers the lookback period trap, the stability clause, and the biologic loophole. Each one has caused paid premiums to result in rejected claims.

Medical disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Travel insurance policy terms vary significantly between providers and jurisdictions. Always read your policy wording in full and consult your IBD specialist and a qualified insurance broker before purchasing cover.

The lookback period: the definition that overrides your declaration

Travel insurance does not use the same definition of pre-existing condition as your national health system. Instead, it applies a specific timeframe called a lookback period, typically 60 to 180 days^[1] before the policy's effective date. Any medical event inside that window can affect coverage, regardless of what you declared.

The practical problem for IBD is that Crohn's disease and ulcerative colitis are rarely static. A dose adjustment, a new prescription, a GP call about symptoms, or a specialist review of bloods can all register as medical activity inside the lookback window. If your medical records show any changes or treatments within the lookback period, the claim will likely be denied^[1] even if you declared your condition correctly.

A shorter lookback window is more favourable for anyone with active disease management. When comparing policies, this is the number to ask for first.

The stability clause: well-controlled does not mean covered

Most policies define a condition as "stable" only if there has been no change in symptoms, no new treatment, and no change to medication dosage during the lookback period. A condition can be well-managed but still excluded if medication was adjusted in the lookback period^[2]. This wording catches IBD patients specifically, because routine monitoring often results in dose tweaks that do not feel clinically significant but are legally significant to the insurer.

The stability clause is where the claims dispute usually happens. You declare Crohn's disease truthfully. You believe your condition is controlled. The insurer reviews your records, finds an azathioprine dose increase three months before departure, and applies the exclusion.

Read the exact wording of the stability definition before you buy. Some policies define it as no hospitalisation in the past six months. Others define it as no change to any medication. The difference matters.

The biologic loophole: when your treatment triggers an automatic exclusion

Insurers ask specifically whether you receive regular drug injections or infusions to treat your condition^[3]. For patients on biologics such as infliximab, adalimumab, or vedolizumab, the answer is yes. Some standard policies exclude all claims linked to any condition treated by injectable or infused medication, regardless of how stable the underlying disease is.

This is not universal across all insurers. Specialist providers that underwrite IBD individually will assess biologic use as part of a full medical screening rather than applying a blanket exclusion. The standard comparison-site policies that auto-generate a quote in under two minutes are the ones most likely to contain this clause.

If you are on a biologic, seek a policy that requires a full telephone or written screening. Any policy that does not ask about your specific medication is almost certainly not accounting for it either.

What happens when you are awaiting tests or a diagnosis change

If you are awaiting the results of tests for your IBD or have been told your treatment plan may change, many insurers will not provide cover until you have results back, or will charge significantly more^[4]. This includes pending colonoscopies, calprotectin results, or planned biologic switches.

An unresolved diagnostic picture is a material fact. Providing incomplete answers at the screening stage can invalidate the entire policy, not just the IBD-related sections.

The pre-existing condition waiver and when it applies

A pre-existing condition waiver removes the standard exclusion and extends benefits to cover flare-ups that disrupt a trip. The waiver is usually only available if you purchase your policy within 14 to 21 days of your initial trip deposit^[5] and insure 100% of your prepaid, non-refundable costs. Missing the purchase window is the single most common reason IBD travellers lose this protection.

This mechanism is more common in markets such as the United States. In markets such as the United Kingdom and Australia, specialist medical underwriting is the standard route, where an insurer individually assesses your IBD, your current medications, and your flare history before agreeing coverage terms.

What insurers actually look at when assessing IBD

During the medical screening process, insurers will typically ask about hospitalisation in the last 12 months, surgery history, bowel obstruction history, and current medications^[6]. Each of these carries a different risk weighting in the underwriter's model.

The factors that typically produce the highest premiums or outright refusals are: a hospitalisation or surgery within the past six months, a biologic infusion schedule that cannot be paused, a bowel obstruction in the past year, and an unresolved diagnostic investigation. Stable, medically managed Crohn's with no recent hospital admissions is the profile that yields the most competitive terms.

Importantly, the insurer will not see your full medical records at the point of sale. Those records are requested only if you make a claim. Your answers at screening must match what those records will show, or the claim can be voided on grounds of non-disclosure.

Conditions that travel insurance policies commonly exclude from IBD cover

Even a correctly declared and underwritten policy will not pay if you travel against your doctor's advice, fail to take prescribed medication, or travel specifically to receive planned treatment^[7]. These are standard exclusions across most policies worldwide.

For IBD specifically, dehydration and electrolyte imbalance claims are sometimes denied because the insurer argues the risk was foreseeable and the traveller did not take reasonable precautions. Check whether your policy covers secondary complications of a flare, not just the flare itself.

How to document your condition before you travel

Carry a letter from your gastroenterologist confirming your diagnosis, your current medications, and your disease status at the time of travel. This letter has two functions: it supports your insurance claim if you need treatment abroad, and it covers medication import rules at customs for biologics and controlled medications. Nomedic's dedicated guide for travelling with biologics explains these rules in further detail.

Storing your medical history in a structured digital format, such as an International Patient Summary (IPS), means that emergency clinicians abroad can read your diagnosis, your current medications, and your allergy profile in a standardised format. Nomedic generates an IPS from your records so you carry it on your phone. It does not replace a letter from your gastroenterologist, but it provides structured backup that paper cannot.

The Crohn's & Colitis Foundation recommends carrying a letter from your IBD team confirming your diagnosis and your flare management plan. Ask your IBD team for a written flare-up plan if you do not already have one^[8]. This plan also matters to your insurer: it demonstrates that you are being managed proactively, which can support a claim disputing the "foreseeable risk" argument.

Three checks before you finalise your policy

Confirm the lookback period length. Ask the insurer directly: 60 days, 90 days, or 180 days. Compare this against any recent medication changes.

Read the stability definition verbatim. "No hospitalisation" is a different standard from "no medication change". The first is achievable for most IBD patients. The second may not be.

Ask whether secondary complications of a flare are covered. Dehydration, anaemia requiring transfusion, and infection secondary to immunosuppression are all realistic IBD travel events. If the policy only covers the primary flare, you may still face large out-of-pocket costs.

Frequently asked questions

What is a pre-existing condition waiver and how does it work for IBD travellers?

A pre-existing condition waiver removes the standard exclusion so that a flare disrupting your trip is covered. To qualify, you typically need to purchase the policy within 14 to 21 days of your first trip deposit and insure the full non-refundable trip cost. Missing this purchase window means losing the waiver eligibility entirely, even if your IBD is otherwise well-controlled.

Is Crohn's disease in remission still a pre-existing condition for travel insurance?

Yes. Remission does not remove Crohn's disease from the pre-existing condition category. You must still declare it. However, remission does improve your underwriting profile: no recent hospitalisation and no medication changes during the lookback period are the key factors that make a policy more accessible and affordable.

Can my travel insurance claim be rejected even if I declared my Crohn's disease?

Yes. Declaring your condition is necessary but not sufficient. If your medical records show a medication change or hospitalisation inside the policy's lookback period, typically 60 to 180 days before purchase, the insurer can apply a stability exclusion and deny the claim. Read the stability definition in the policy wording, not just the declaration requirements.

Do I need to declare my biologic infusion or injection for travel insurance?

Yes. Many screening questionnaires ask directly whether you receive regular injections or infusions to treat a medical condition. If you are on adalimumab, infliximab, vedolizumab, or a similar biologic, you must answer yes. Some standard policies then exclude all claims linked to that condition. Specialist IBD insurers underwrite this individually rather than applying a blanket exclusion.

Can I get travel insurance if I'm waiting for IBD test results or a colonoscopy?

This depends on the insurer. Many will decline to underwrite IBD cover until you have received the results of any pending investigation. Travelling with unresolved diagnostic tests is considered an undisclosed material fact, and a claim linked to your IBD could be voided if you did not disclose this at screening.

Does travel insurance cover a Crohn's flare-up while I'm abroad?

It depends on the policy and whether your condition was properly declared and met the stability criteria at the time of purchase. Policies that include pre-existing condition cover, or that have been individually underwritten for IBD, will cover emergency treatment for a flare. Standard comparison-site policies that auto-quote without a medical screening frequently exclude pre-existing conditions or apply blanket restrictions to conditions treated by injectable medication.